Patented Drug Sales Forecast To Decline

Despite a compound annual growth rate (CAGR) of 3.61% in local currency terms and of 6.1% in US dollar terms from 2004-2009, BMI's outlook for the Netherlands' patented drug market is less optimistic over the next five years. From 2009-2014 a CAGR of -3.31% is projected in local currency terms (-5.35% in US dollar terms), largely as a result of the impending patent cliff. BMI calculates that patented drug sales in the Netherlands reached a value of EUR4.07bn (US$5.73bn) in 2009 and that by 2014 the sale of patented drugs will fall to a value of EUR3.44bn (US$4.35bn). In 2009,

To read the full article, please choose one of the following options: